BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Galectin Therapeutics 

7 Wells Avenue, Suite #34

Newton  Massachusetts  02459  U.S.A.
Phone: 617-559-0033 Fax: 617-928-3450


SEARCH JOBS










 Company News
Galectin Therapeutics Announces First Patient Dosed In Cohort 1 Of Phase 1B Clinical Trial Of GR-MD-02 In Combination With Ipilimumab In Metastatic Melanoma 7/22/2014 11:20:42 AM
Galectin Therapeutics Added To Russell 2000 Index 7/9/2014 10:33:53 AM
Galectin Therapeutics Announces That Oral Treatment With Galectin-3 Inhibitor GR-MD-02 Is Efficacious In Preclinical Model Of Fatty Liver Disease With Fibrosis 6/23/2014 7:30:41 AM
Galectin Therapeutics To Present At Jefferies and Co. 2014 Global Healthcare Conference 5/29/2014 9:24:44 AM
Galectin Therapeutics Receives U.S. Patent For GR-MD-02 In Diabetic Nephropathy, A Progressive Kidney Disease 5/28/2014 9:15:23 AM
Galectin Therapeutics To Hold Conference Call To Provide Corporate Update Following Company's Annual Meeting Of Shareholders 5/8/2014 10:06:12 AM
Galectin Therapeutics Completes Enrollment Of Second Cohort Of Phase 1 Trial Of GR-MD-02 For NASH (Fatty Liver Disease) With Advanced Fibrosis 4/23/2014 9:21:44 AM
Galectin Therapeutics Announces First Patient Dosed In Second Cohort Of Phase 1 Trial Of GR-MD-02 For NASH With Advanced Fibrosis 4/17/2014 9:27:45 AM
First Cohort Results In Galectin Therapeutics' Phase 1 Trial Reveal Biomarker Evidence Of Therapeutic Effect On Fibrosis And Inflammation In Nash With Advanced Fibrosis 4/1/2014 11:03:25 AM
Galectin Therapeutics To Announce Results From First Cohort Of Phase 1 Clinical Trial In Fatty Liver Disease 3/25/2014 9:20:23 AM
12345678910